You are here

Article Text

Article menu
Download PDFPDF
Letters
Relapse patterns in IgG4-related disease
  1. Motohisa Yamamoto1,
  2. Hiroki Takahashi1,
  3. Keisuke Ishigami1,
  4. Hidetaka Yajima1,
  5. Yui Shimizu1,
  6. Tetsuya Tabeya1,
  7. Mikiko Matsui1,
  8. Chisako Suzuki1,
  9. Yasuyoshi Naishiro1,
  10. Kohzoh Imai2,
  11. Yasuhisa Shinomura1
  1. 1First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
  2. 2Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
  1. Correspondence to Motohisa Yamamoto, First Department of Internal Medicine, Sapporo Medical University School of Medicine, South 1- West 16, Chuo-ku, Sapporo, Hokkaido, 0608543, Japan; mocha{at}cocoa.plala.or.jp

https://doi.org/10.1136/annrheumdis-2012-201694

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Immunoglobulin (Ig)G4-related disease (IgG4-RD) is a chronic inflammatory disorder characterised by elevated levels of serum IgG4 and swollen organs with fibrosis and infiltration by abundant IgG4-positive plasmacytes.1 ,2 Glucocorticoid treatment is effective for achieving clinical remission in the short term,3 but about 20%–30% of cases present with relapse after steroid doses are reduced.4 Serial changes of serum IgG4 levels are often considered to reflect the disease activity in routine clinical practice,5 but how disease relapse occurs is not well understood. We therefore analysed relapse patterns in IgG4-RD on the basis of data from the Sapporo Medical university And …

    View Full Text

    Footnotes

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval Written consent to use the information from these cases was obtained from the patients in accordance with the Declaration of Helsinki. This study proceeded under the approval of our institutional IRB (SMU 22-57).

    • Provenance and peer review Not commissioned; externally peer reviewed.